Eli Lilly and Co. (LLY), Friday announced the decision to increase investment in Lebanon, Indiana manufacturing facility from $3.7 billion to $9 billion to enhance production of Zepbound and Mounjaro injections used for the treatment of obesity and type-2 diabetes, respectively.
Through the investment, Lilly expects to create an additional 200 full-time jobs and more than 5,000 construction jobs during the site's development.
Additionally, the company is planning to expand across new locations such as Research Triangle Park and Concord, North Carolina; Limerick, Ireland; and Alzey, Germany.
Currently, Lilly's stock is moving down 0.05 percent, to $808.02 on the New York Stock Exchange.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.